Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.
Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Rhea-AI Summary
Kane Biotech Inc. announces the introduction of its revyve™ Antimicrobial Wound Gel Spray at the Boswick Burn and Wound Care Symposium. The spray gel, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, has been patented and is designed to simplify application to wounds, reduce infection risk, and minimize pain for patients. The product is pending FDA clearance and is expected to have a significant impact on treating sensitive wounds, particularly burns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Kane Biotech Inc. announces the presentation of its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The gel, featuring thermo-reversible properties, is designed for sensitive wounds such as burns and offers prolonged antimicrobial activity in a moist environment. Dr. Gregory Schultz, Chief Scientific Officer, expresses excitement for the presentation and anticipates a positive reception within the wound care community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. announces a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director. Dr. Huizinga has an extensive background in the pharmaceutical industry and has been a member of Kane Biotech’s Scientific Advisory Board since 2018.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) corrects the maturity date of its credit facility to March 31, 2024, not March 31, 2023 as previously stated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) announces an agreement with Pivot I Financial Limited Partnership to extend the maturity date of its credit facility, allowing the company to work towards closing a share purchase agreement for its interest in STEM Animal Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) has signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. The terms of the offer remain confidential but specify that Kane will sell its ownership of STEM. The company will receive a deposit of US $625,000 which will be applied towards the sale price of Kane’s interest in STEM. This move allows Kane to focus on human health, specifically wound care and dermatology solutions, two areas where biofilms significantly impact patient health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.36%
Tags
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) announced a 29% increase in product and services revenue and a 26% increase in total revenue for the third quarter of 2023. The company's gross profit increased by 17%, but total operating expenses also rose by 35%, leading to a 41% increase in loss compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (KNE) will announce its Q3 2023 financial results on November 28, 2023. The company focuses on technologies and products to prevent and remove microbial biofilms. Kane Biotech management will host a conference call to review the financial results and discuss business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) announces the appointment of John Coleman, an accomplished executive with over two decades of senior biotechnology expertise, to its Board of Directors. Dr. Coleman brings scientific and business expertise, having served as the President and CEO of Avivo Biomedical Inc. and co-founded Anandia Labs. His appointment is expected to contribute to Kane's vision of bringing transformative biofilm-targeted products to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel. The gel combines advanced technology with an affordable price point and is intended for clinical usage in the treatment of chronic wounds. The product will be presented at the Symposium on Advanced Wound Care (SAWC) Fall forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of KANE BIOTECH ORD (KNBIF)?
The current stock price of KANE BIOTECH ORD (KNBIF) is $0.0767 as of November 22, 2024.
What is the market cap of KANE BIOTECH ORD (KNBIF)?
The market cap of KANE BIOTECH ORD (KNBIF) is approximately 10.2M.
What is Kane Biotech Inc. known for?
Kane Biotech is recognized for its research, development, and commercialization of technologies and products that prevent and remove microbial biofilms.
What are some of the key products offered by Kane Biotech?
Some of the key products offered by Kane Biotech include StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™.
Where is Kane Biotech listed?
Kane Biotech is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent achievements has Kane Biotech announced?
Kane Biotech recently announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel.
Who is the President and CEO of Kane Biotech?
The President and CEO of Kane Biotech is Marc Edwards.
What sets Kane Biotech apart in the biotechnology industry?
Kane Biotech stands out for its focus on biofilm research and its innovative portfolio of intellectual property and products.
How can investors participate in Kane Biotech's growth?
Investors can engage with Kane Biotech by trading its shares on the TSX Venture Exchange under the symbol 'KNE' or on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent financial results has Kane Biotech shared?
Kane Biotech announced its fourth quarter and full year 2023 financial results, as well as its first quarter 2024 financial results.
Where can I find more information about Kane Biotech?
For more information about Kane Biotech, visit their website or explore their filings on SEDAR.
What industry does Kane Biotech operate in?
Kane Biotech operates in the biotechnology industry, specifically focusing on technologies and products related to microbial biofilms.
KANE BIOTECH INC ORD